Today: Dec 1, 2022
Last update: Nov 22, 2022
Ethical and Legal Aspects of Using Genome Editing Technologies in Medicine (Review)

Ethical and Legal Aspects of Using Genome Editing Technologies in Medicine (Review)

Karagyaur M.N., Efimenko A.Yu., Makarevich P.I., Vasiluev P.A., Akopyan Zh.A., Bryzgalina E.V., Tkachuk V.A.
Key words: genome editing technologies; embryo genome modification; CRISPR/Cas9; legal regulation of GMO; ethical standards in medicine.
2019, volume 11, issue 3, page 117.

Full text

html pdf

According to many experts, the turning point in the development of genome editing technologies (GET) was 2012, when Feng Zhang and Jennifer Doudna independently proposed the adaptive bacterial immunity system CRISPR/Cas9 for editing the genome of living cells of eukaryotic organisms. Since then, the range of applications of CRISPR/Cas9 technology and related GET has continued to grow like an avalanche. Thus, new genetically modified microorganisms, plants, and animals have been created, the experimental studies on the genetic foundations of life have greatly expanded, and revolutionary approaches to therapy and prevention of incurable diseases have been developed.

However, the indisputable advantages of GET are associated with high risks (real and potential) to the environment, human health, and society as a whole. Significant progress in the genome editing in eukaryotes has led to a rapid appearance of humans with an “improved” genome, despite the openly expressed opposition of leading scientists working in this field. Among them, David Baltimore, Paul Berg, Jennifer Doudna, George Church, and Martin Jinek are calling for a global suspension of work with human embryos until the technical, legal and ethical standards in this area are developed.

There is an urgent need for the development of an unambiguous public position and improvement of the regulatory framework for the GET, including that in the Russian Federation; the present review attempts to address the urgent issue of GET-related regulations.

We discuss various approaches to regulating the use of GET in medicine. We review legal acts and ethical recommendations around the world concerning the GET-mediated modification of the plant and animal genetic material for the purpose of creating medical products and drugs. We also address the sensitive issue of editing the genome of human cells (somatic or germ). Special attention is paid to the relevant legal and ethical standards exiting in the Russian Federation.

The presented data allow for a better understanding of the current situation and the areas of further research into GET, where the development and implementation of regulatory standards are especially urgent.

  1. Bhat S.A., Malik A.A., Ahmad S.M., Shah R.A., Ganai N.A., Shafi S.S., Shabir N. Advances in genome editing for improved animal breeding: a review. Vet World 2017; 10(11): 1361–1366,
  2. Donohoue P.D., Barrangou R., May A.P. Advances in industrial biotechnology using CRISPR-Cas systems. Trends Biotechnol 2018; 36(2): 134–146,
  3. Wang C.X., Cannon P.M. Clinical applications of genome editing to HIV cure. AIDS Patient Care STDS 2016; 30(12): 539–544,
  4. Hammond A.M., Kyrou K., Bruttini M., North A., Galizi R., Karlsson X., Kranjc N., Carpi F.M., D’Aurizio R., Crisanti A., Nolan T. The creation and selection of mutations resistant to a gene drive over multiple generations in the malaria mosquito. PLoS Genet 2017; 13(10): e1007039,
  5. Cyranoski D. The CRISPR-baby scandal: what’s next for human gene-editing. Nature 2019; 566(7745): 440–442,
  6. Zayner J. URL: crispr-kits-learn-modern-science-by-doing.
  7. Berg P., Singer M.F. The recombinant DNA controversy: twenty years later. Proc Natl Acad Sci U S A 1995; 92(20): 9011–9013,
  8. Charo R.A. The legal and regulatory context for human gene editing. Issues in Science and Technology 2016; 32(3): 39–44.
  9. Baltimore D., Berg P., Botchan M., Carroll D., Charo R.A., Church G., Corn J.E., Daley G.Q., Doudna J.A., Fenner M., Greely H.T., Jinek M., Martin G.S., Penhoet E., Puck J., Sternberg S.H., Weissman J.S., Yamamoto K.R. A prudent path forward for genomic engineering and germline gene modification. Science 2015; 348(6230): 36–38,
  10. The National Academies of Sciences, Engineering, Medicine. International Summit on Human Gene Editing: a global discussion. 2015. URL:
  11. The National Academies of Sciences, Engineering, Medicine. Statement by the organizing committee of the Second International Summit on Human Genome Editing. 2018. URL: /newsitem.aspx?RecordID=11282018b.
  12. Allen & Overy. Regulating CRISPR genome editing in humans: where do we go from here? 2017. URL: gb/Pages/August-2017-Regulating-CRISPR-genome- editing-in-humans-where-do-we-go-from-here--.aspx.
  13. Nesbit R. It’s time for rational regulation. The Biologist 2017; 64(4): 10. URL: opinion/1789-it-s-time-for-rational-regulation.
  14. Ishii T., Pera R.A.R., Greely H.T. Ethical and legal issues arising in research on inducing human germ cells from pluripotent stem cells. Cell Stem Cell 2013; 13(2): 145–148,
  15. Bio-IT World Staff. How the world’s governments have regulated human genome editing. 2016. URL: governments-have-regulated-human-genome-editing.html.
  16. Wired. CRISPR gene-editing gets rules. Well, guidelines, really. 2015. URL: the-beginning-of-some-rules/.
  17. Blackwell T. End Canada’s criminal ban on contentious CRISPR gene-editing research, major science group urges. 2017. URL: contentious-crispr-gene-editing-research-major-science-group-urges.
  18. McNally K. The future of genome editing and how it will be regulated. 2017. URL:
  19. European Medicines Agency. Accelerated assessment. 2016. URL: marketing-authorisation/accelerated-assessment.
  20. Sipp D. Conditional approval: Japan lowers the bar for regenerative medicine products. Cell Stem Cell 2015; 16(4): 353–356,
  21. Biffi A., Montini E., Lorioli L., Cesani M., Fumagalli F., Plati T., Baldoli C., Martino S., Calabria A., Canale S., Benedicenti F., Vallanti G., Biasco L., Leo S., Kabbara N., Zanetti G., Rizzo W.B., Mehta N.A., Cicalese M.P., Casiraghi M., Boelens J.J., Del Carro U., Dow D.J., Schmidt M., Assanelli A., Neduva V., Di Serio C., Stupka E., Gardner J., von Kalle C., Bordignon C., Ciceri F., Rovelli A., Roncarolo M.G., Aiuti A., Sessa M., Naldini L. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341(6148): 1233158,
  22. Davila M.L., Sadelain M. Biology and clinical application of CAR T cells for B cell malignancies. Int J Hematol 2016; 104(1): 6–17,
  23. Hirsch T., Rothoeft T., Teig N., Bauer J.W., Pellegrini G., De Rosa L., Scaglione D., Reichelt J., Klausegger A., Kneisz D., Romano O., Secone Seconetti A., Contin R., Enzo E., Jurman I., Carulli S., Jacobsen F., Luecke T., Lehnhardt M., Fischer M., Kueckelhaus M., Quaglino D., Morgante M., Bicciato S., Bondanza S., De Luca M. Regeneration of the entire human epidermis using transgenic stem cells. Nature 2017; 551(7680): 327–332,
  24. Waltz E. USDA approves next-generation GM potato. Nat Biotechnol 2015; 33(1): 12–13,
  25. Fagan J. Summary of the tryptophan toxicity incident. URL:
  26. FDA. Regulation of intentionally altered genomic DNA in animals. 2017. URL: Enforcement/GuidanceforIndustry/ucm113903.pdf.
  27. GMO FAQs. How are governments regulating CRISPR and new breeding technologies (NBTs)? URL: how-are-governments-regulating-crispr-and-new- breeding-technologies-nbts/.
  28. Carroll D., Charo R.A. The societal opportunities and challenges of genome editing. Genome Biol 2015; 16(1): 242,
  29. Sprink T., Eriksson D., Schiemann J., Hartung F. Regulatory hurdles for genome editing: process- vs. product-based approaches in different regulatory contexts. Plant Cell Rep 2016; 35(7): 1493–1506,
  30. Araki M., Ishii T. Towards social acceptance of plant breeding by genome editing. Trends Plant Sci 2015; 20(3): 145–149,
  31. Barton J., Crandon J., Kennedy D., Miller H. A model protocol to assess the risks of agricultural introductions: a risk-based approach to rationalizing field trial regulations. Nat Biotechnol 1997; 15(9): 845–848,
  32. Huang S., Weigel D., Beachy R.N., Li J. A proposed regulatory framework for genome-edited crops. Nat Genet 2016; 48(2): 109–111,
  33. 2019. URL:
  34. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 2013; 310(20): 2191–2194,
  35. World Medical Association. Medical ethics manual. 2015. URL: 2016/11/Ethics_manual_3rd_Nov2015_en.pdf.
  36. Rossant J. Gene editing in human development: ethical concerns and practical applications. Development 2018; 145(16): dev150888,
  37. Schuttelaar and Partners. The regulatory status of new breeding techniques in countries outside the European Union. 2015. URL: rep-regulatory-status-of-nbts-oustide-the-eu-june-2015.pdf.
  38. U.S. Environmental Protection Agency. Modernizing the regulatory system for biotechnology products: final version of the update to the coordinated framework for the regulation of biotechnology. 2017. URL: and-fifra/modernizing-regulatory-system-biotechnology-products.
  39. Library of Congress. Restrictions on genetically modified organisms. 2014. URL:
  40. Jin S. The ethical implications of a new gene editing technique. 2015. URL: implications-of-a-new-gene-editing-technique/.
  41. Peschin S. How should we regulate genome editing? 2017. URL: how-should-we-regulate-genome-editing/.
  42. Court of Justice of European Union. Organisms obtained by mutagenesis are GMOs and are, in principle, subject to the obligations laid down by the GMO Directive. 2018. URL: docs/application/pdf/2018-07/cp180111en.pdf.
  43. Federal’nyy zakon RF ot 17.12.1997 No.149-FZ “O semenovodstve”. Sobranie zakonodatel’stva RF 1997, No.51, st. 5715 [Federal Law of the Russian Federation dated December 17, 1997 No.149-FZ “On seed production”. Legislative Acts of the Russian Federation 1997, No.51, Art. 5715].
  44. Federal’nyy zakon RF ot 10.01.2002 No.7-FZ “Ob okhrane okruzhayushchey sredy”. Sobranie zakonodatel’stva RF 2002, No.47, st. 4659 [Federal Law of the Russian Federation dated January 10, 2002 No.7-FZ “On environmental protection”. Legislative Acts of the Russian Federation 2002, No.47, Art. 4659].
  45. Federal’nyy zakon RF ot 05.07.1996 (v red. ot 29.06.2017) No.86-FZ “O gosudarstvennom regulirovanii v oblasti genno-inzhenernoy deyatel’nosti”. Sobranie zakonodatel’stva RF 1996, No.28, st. 3348 [Federal Law of the Russian Federation dated 5 July, 1996 (as amended on June 29, 2017) No.86-FZ “On state regulation in the field of genetic engineering”. Legislative Acts of the Russian Federation 1996, No.28, Art. 3348].
  46. Customs Union Commission. TR TS 021/2011 “O bezopasnosti pishchevoy produktsii” [TR TS 021/2011 “About food safety”]. URL: Documents/TR%20TS%20PishevayaProd.pdf.
  47. Kalinina N., Klink G., Glukhanyuk E., Lopatina T., Efimenko A., Akopyan Z., Tkachuk V. MiR-92a regulates angiogenic activity of adipose-derived mesenchymal stromal cells. Exp Cell Res 2015; 339(1): 61–66,
  48. Kalinina N., Kharlampieva D., Loguinova M., Butenko I., Pobeguts O., Efimenko A., Ageeva L., Sharonov G., Ischenko D., Alekseev D., Grigorieva O., Sysoeva V., Rubina K., Lazarev V., Govorun V. Characterization of secretomes provides evidence for adipose-derived mesenchymal stromal cells subtypes. Stem Cell Res Ther 2015; 6: 1–12,
  49. Eremichev R.Y., Makarevich O.A., Alexandrushkina N.A., Kulebyakin K.Y., Dyikanov D.T., Makarevich P.I. Menstrual-blood serum displays an antifibrotic effect on human endometrial mesenchymal stromal cells. Cell Tissue Biol 2018; 12(4): 281–288,
  50. The National Academies of Sciences, Engineering, Medicine Report. Human genome editing: science, ethics and governance. National Academies Press; 2017,
  51. Rysenkova K.D., Semina E.V., Karagyaur M.N., Shmakova A.A., Dyikanov D.T., Vasiluev P.A., Rubtsov Y.P., Rubina K.A., Tkachuk V.A. CRISPR/Cas9 nickase mediated targeting of urokinase receptor gene inhibits neuroblastoma cell proliferation. Oncotarget 2018; 9(50): 29414–29430,
  52. Tyurin-Kuzmin P.A., Karagyaur M.N., Rubtsov Y.P., Dyikanov D.T., Vasiliev P.A., Vorotnikov A.V. CRISPR/Cas9-mediated modification of the extreme C-terminus impairs PDGF-stimulated activity of Duox2. Biol Chem 2018; 399(5): 437–446,
  53. Califf R.M., Nalubola R. FDA’s science-based approach to genome edited products. 2017. URL: science-based-approach-to-genome-edited-products/.
  54. O’Rourke D.M., Nasrallah M.P., Desai A., Melenhorst J.J., Mansfield K., Morrissette J.J.D., Martinez-Lage M., Brem S., Maloney E., Shen A., Isaacs R., Mohan S., Plesa G., Lacey S.F., Navenot J.M., Zheng Z., Levine B.L., Okada H., June C.H., Brogdon J.L., Maus M.V. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017; 9(399): eaaa0984,
  55. Ho B.X., Loh S.J.H., Chan W.K., Soh B.S. In vivo genome editing as a therapeutic approach. Int J Mol Sci 2018; 19(9): E2721,
  56. Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature 2016; 539(7630): 479,
  57. Reardon S. First CRISPR clinical trial gets green light from US panel. Nature (News) 2016,
  58. Rossidis A.C., Stratigis J.D., Chadwick A.C., Hartman H.A., Ahn N.J., Li H., Singh K., Coons B.E., Li Li, Lv W., Zoltick P.W., Alapati D., Zacharias W., Jain R., Morrisey E.E., Musunuru K., Peranteau W.H. In utero CRISPR-mediated therapeutic editing of metabolic genes. Nat Med 2018; 24(10): 1513–1518,
  59. Hill M.A. Embryology ovary development. URL: index.php/Ovary_Development#Human_Ovary_Timeline.
  60. Hill M.A. Embryology testis development. URL: embryology/index.php/Testis_Development.
  61. World Medical Association. WMA Declaration of Geneva. 2018. URL:
  62. Department of Health, Education, and Welfare; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research. J Am Coll Dent 2014; 81(3): 4–13.
  63. Raposo V.L., Osuna E. European convention of human rights and biomedicine. Legal and Forensic Medicine 2013; 1405–1423,
  64. Bosley K.S., Botchan M., Bredenoord A.L., Carroll D., Charo R.A., Charpentier E., Cohen R., Corn J., Doudna J., Feng G., Greely H.T., Isasi R., Ji W., Kim J.S., Knoppers B., Lanphier E., Li J., Lovell-Badge R., Martin G.S., Moreno J., Naldini L., Pera M., Perry A.C., Venter J.C., Zhang F., Zhou Q. CRISPR germline engineering — the community speaks. Nat Biotechnol 2015; 33(5): 478–486,
  65. Specter M. The gene hackers. 2015. URL: /2015/11/16/the-gene-hackers.
  66. Kaiser J. U.S. panel gives yellow light to human embryo editing. Science 2017,
  67. Bamford K.B., Wood S., Shaw R.J. Standards for gene therapy clinical trials based on pro-active risk assessment in a London NHS Teaching Hospital Trust. QJM 2005; 98(2): 75–86,
  68. Human Tissue Authority. Regulation of regenerative medicine in the UK. URL: _of_regulators_in_regenerative_medicine.pdf.
  69. Pocklington D. Genome editing of human cells. 2015. URL:
  70. Department of Health & Social Care UK. British Society for Gene and Cell Therapy (BSGCT). Public engagement day 2019. 2019. URL:
  71. FDA. Gene therapy clinical trials — observing subjects for delayed adverse events. Guidance for industry. 2006. URL: BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ Guidances/CellularandGeneTherapy/ucm078719.pdf.
  72. FDA. Points to consider in human somatic cell therapy and gene therapy. Hum Gene Ther 1991; 2(3): 251–256,
  73. FDA. Considerations for the design of early-phase clinical trials of cellular and gene therapy products. 2015. URL: GuidanceComplianceRegulatoryInformation/ Guidances/CellularandGeneTherapy/UCM564952.pdf.
  74. FDA. Fast track, breakthrough therapy, accelerated approval, priority review. 2015. URL:
  75. Federal’nyy zakon RF ot 23.06.2016 No.180-FZ “O biomeditsinskikh kletochnykh produktakh”. Sobranie zakonodatel’stva RF 2016, No.26, st. 3849 [Federal Law of the Russian Federation dated June 23, 2016 No.180-FZ “On biomedical cell products”. Legislative Acts of the Russian Federation 2016, No.26, Art. 3849].
  76. Makarevich P., Akopyan Z., Tkachuk V. On new regulation of cell therapy and regenerative medicine in the Russian Federation. Cytotherapy 2017; 19(9): 1125–1126,
  77. Federal’nyy zakon RF ot 12.04.2010 No.61-FZ “Ob obrashchenii lekarstvennykh sredstv”. Sobranie zakonodatel’stva RF 2010, No.16, st. 1815 [Federal Law of the Russian Federation dated April 12, 2010 No.61-FZ “On circulation of medicines”. Legislative Acts of the Russian Federation 2010, No.16, Art. 1815].
  78. Federal’nyy zakon RF ot 21.11.2011 (v red. ot 05.12.2017) No.323-FZ “Ob osnovakh okhrany zdorov’ya grazhdan v Rossiyskoy Federatsii”. Sobranie zakonodatel’stva RF 2011, No.48, st. 6724 [Federal Law of the Russian Federation dated November 21, 2011 (as amended on December 5, 2017) No.323-FZ “On the basics of public health care in the Russian Federation”. Legislative Acts of the Russian Federation 2011, No.48, Art. 6724].
  79. EAEU. Pravila provedeniya issledovaniy biologicheskikh lekarstvennykh sredstv na territorii Evraziyskogo ekonomicheskogo soyuza. Reshenie No.89 ot 03.11.2016 [Rules for conducting research on biopharmaceuticals in the territory of the Eurasian Economic Union. Resolution No.89 dated November 3, 2016]. URL:
  80. Rubin C. Editing the book of life. URL: 2017,
  81. Andoh C.T. Genome editing technologies: ethical and regulation challenges for Africa. International Journal of Health Economics and Policy 2017; 2(2): 30–46.
  82. 2019. URL:
  83. Karagyaur M., Rubtsov Y., Vasiliev P., Tkachuk V. Practical recommendations for improving efficiency and accuracy of the CRISPR/Cas9 genome editing system. Biochemistry (Mosc) 2018; 83(6): 629–642,
  84. Dyikanov D.T., Vasiluev P.A., Rysenkova K.D., Aleksandrushkina N.A., Tyurin-Kuzmin P.A., Kulebyakin K.Y., Rubtsov Y.P., Shmakova A.A., Evseeva M.N., Balatskiy A.V., Semina E.V., Rostovtseva A.I., Makarevich P.I., Karagyaur M.N. Optimization of CRISPR/Cas9 technology to knock-out genes of interest in aneuploid cell lines. Tissue Eng Part C Methods 2019; 25(3): 168–175,
  85. de Lecuona I., Casado M., Marfany G., Lopez Baroni M., Escarrabill M. Gene editing in humans: towards a global and inclusive debate for responsible research. Yale J Biol Med 2017; 90(4): 673–681.
  86. Missmer S.A., Pearson K.R., Ryan L.M., Meeker J.D., Cramer D.W., Hauser R. Analysis of multiple-cycle data from couples undergoing in vitro fertilization: methodologic issues and statistical approaches. Epidemiology 2011; 22(4): 497–504,
  87. Ormond K.E., Mortlock D.P., Scholes D.T., Bombard Y., Brody L.C., Faucett W.A., Garrison N.A., Hercher L., Isasi R., Middleton A., Musunuru K., Shriner D., Virani A., Young C.E. Human germline genome editing. Am J Hum Genet 2017; 101(2): 167–176,
  88. Sample I. Genetically modified babies given go ahead by UK ethics body. 2018. URL: modified-babies-given-go-ahead-by-uk-ethics-body.
  89. Araki M., Ishii T. International regulatory landscape and integration of corrective genome editing into in vitro fertilization. Reprod Biol Endocrinol 2014; 12(1): 108,
  90. Blakemore E. First human embryos “edited” in U.S. — get the facts. 2017. URL: gene-editing-crispr-us-health-science/?user.testname=none.
  91. Prikaz Ministerstva zdravoohranenija RF ot 30 avgusta 2012 g. No.107n g. Moskva “O porjadke ispol’zovanija vspomogatel’nyh reproduktivnyh tehnologij, protivopokazanijah i ogranichenijah k ih primeneniju” [Order of the Ministry of Health of the Russian Federation dated August 30, 2012 No.107n, Moscow “On the procedure for using assisted reproductive technologies, contraindications and restrictions of their use”] URL: poryadke-ispolzovaniya-vspomogatelnyh-reproduktivnyh-tehnologiy- protivopokazaniyah-i-ogranicheniyah-k-ih-primeneniyu.
  92. Federal’nyj zakon RF ot 20.05.2002 №54-FZ “O vremennom zaprete na klonirovanie cheloveka”. Sobranie zakonodatel’stva RF 2002, No.21, st. 1917 [Federal Law of the Russian Federation dated May 20, 2002 No.54-FZ “On a temporary ban on human cloning”. Legislative Acts of the Russian Federation 2002, No.21, Art. 1917].
  93. International Society for Stem Cell Research (ISSCR). Guidelines for stem cell research and clinical translation. 2016. URL: all-isscr-guidelines/guidelines-2016/isscr-guidelines-for- stem-cell-research-and-clinical-translation.pdf?sfvrsn=4.
  94. Plomer A. EU ban on stem cell patents is a threat both to science and the rule of law. 2011. URL: blog/2011/dec/12/eu-ban-stem-cell-patents.
  95. International Society for Stem Cell Research (ISSCR). ISSCR comments on U.S. study to correct disease genes in human embryos. 2017. URL: isscr-news-articles/article-listing/2017/08/02/isscr-comments- on-u.s.-study-to-correct-disease-genes-in-human-embryos.
  96. CRISPRcon. 2017. URL:
  97. Cartagena protocol on biosafety to the convention on biological diversity. Montreal; 2000. URL:
  98. World Medical Association. WMA Declaration of Helsinki — ethical principles for medical research involving human subjects. 2018. URL: principles-for-medical-research-involving-human-subjects/.
  99. UNESCO. Universal Declaration on Bioethics and Human Rights. 2005. URL:
  100. Witherspoon Council on Ethics and the Integrity of Science. The stem cell debates: lessons for science and politics. 2012. URL: debates-lessons-for-science-and-politics.
  101. US Environment Protection Agency. The National Environmental Policy Act. 1969. URL: summary-national-environmental-policy-act.
  102. FDA. Federal Food, Drug, and Cosmetic Act. 2018. URL: /federalfooddrugandcosmeticactfdcact/default.htm.
  103. Galli M.G., Serabian M. Regulatory aspects of gene therapy and cell therapy products. Adv Exp Med Biol 2015,
  104. Justice Laws Website. Plant Protection Act. 2019. URL:
  105. Canadian Food Inspection Agency. Regulating agricultural biotechnology in Canada: an overview. 2016. URL: public/overview/eng/1338187581090/1338188593891.
  106. Knoppers B.M., Isasi R., Caulfield T., Kleiderman E., Bedford P., Illes J., Ogbogu U., Ravitsky V., Rudnicki M. Human gene editing: revisiting Canadian policy. NPJ Regen Med 2017; 2(1): 3,
  107. Knoppers B.M., Nguyen M.T., Noohi F., Kleiderman E. Human genome editing: ethical and policy considerations. 2018. URL: en~v~Human_Genome_Editing_-_Policy_Brief.pdf.
  108. Canadian Institutes of Health Research. Human germline gene editing: points to consider from a Canadian perspective. 2016. URL:
  109. Presidency of the Republic Civil Cabinet Sub-Office of Legal Affairs. Law No.11.105. 2005. URL:
  110. National Administration of Drugs, Foods and Medical Devices. Regulation 6677/10. Buenos Aires; 2010. URL:
  111. Ministry of Health. Secretary Office of Policies, Regulations and Institutes. Regulation 7075. Buenos Aires; 2011. URL: 11RegistrationProceduresBiologicalPharmaProducts.pdf.
  112. European Medicines Agency. Guidelines relevant for advanced therapy medicinal products. URL: development/advanced-therapies/guidelines- relevant-advanced-therapy-medicinal-products.
  113. Kipling J. The European landscape for human genome editing. A review of the current state of the regulations and ongoing debates in the EU. 2016. URL:
  114. Parliament of the United Kingdom. Environmental Protection Act 1990. URL:
  115. European Food Safety Authority. GMO applications: regulations and guidance. URL:
  116. Gene therapy legislation in the United Kingdom. URL:
  117. Parliament of the United Kingdom. Human Fertilisation and Embryology Act 2008. URL:
  118. Gene therapy legislation in France. URL:
  119. Mahalatchimy A., Rial-Sebbag E. Regulation of stem cell research in France. 2017. URL:
  120. Gene therapy legislation in Germany. URL:
  121. Small S. Regulation of stem cell research in Germany.
  122. Gene therapy legislation in Sweden. URL:
  123. MPA. The Medical Product Agency’s provisions and guidelines on clinical trials of medicinal products for human use. 2003. URL:
  124. Ministry of Health and Social Affairs. The Genetic Integrity Act (2006:351). 2006. URL:
  125. Small S., Hovatta O. Regulation of stem cell research in Sweden. URL:
  126. Gene therapy legislation in China. URL:
  127. Rosemann A., Sleeboom-Faulkner M. New regulation for clinical stem cell research in China: expected impact and challenges for implementation. Regen Med 2015; 11(1): 5–9,
  128. Ahuja V., Jotwani G. The regulation of genetically modified organisms in India. 2007. URL:
  129. Tiwari S.S., Raman S., Martin P. Regenerative medicine in India: trends and challenges in innovation and regulation. Regen Med 2017; 12(7): 875–885,
  130. Chodisetty S., Nelson E.J. Gene therapy in India: a focus. J Biosci 2014; 39(3): 537–541,
  131. Laurens J.B. A comparative analysis of the regulatory framework of the therapeutic application of stem cell technologies [dissertation]. University of Pretoria; 2017. URL: Laurens_Comparative_2017.pdf?sequence=1&isAllowed=y.
  132. Postanovlenie pravitel’stva RF ot 29.06.2017 No.770 “O vnesenii izmeneniy v postanovlenie Pravitel’stva RF ot 23.09.2013 g. No.839 “O gosudarstvennoy registratsii genno-inzhenerno-modifitsirovannykh organizmov, prednaznachennykh dlya vypuska v okruzhayushchuyu sredu, a takzhe produktsii, poluchennoy s primeneniem takikh organizmov ili soderzhashchey takie organizmy”. 2017 [Directive of the Government of the Russian Federation dated June 29, 2017 No.770 “On amending the directive of the Government of the Russian Federation dated September 23, 2013 No.839 “On state registration of genetically modified organisms intended for release into the environment, as well as products obtained using such organisms or containing such organisms” 2017]. URL: 12ZF6o3Z9m4toLDUehVzzeGLj201gv68.pdf.
Karagyaur M.N., Efimenko A.Yu., Makarevich P.I., Vasiluev P.A., Akopyan Zh.A., Bryzgalina E.V., Tkachuk V.A. Ethical and Legal Aspects of Using Genome Editing Technologies in Medicine (Review). Sovremennye tehnologii v medicine 2019; 11(3): 117,

Journal in Databases